阿替普酶静脉溶栓联合阿托伐他汀钙对急性脑梗死患者炎性水平的作用

Effect of intravenous thrombolysis with alpinase combined with atorvastatin on inflammatory factors in patients with acute cerebral infarction

目的:探索阿替普酶静脉溶栓联合阿托伐他汀治疗急性脑梗死患者的的临床作用。方法:取2019年1月到2021年6月本院收治急性脑梗死患者80例为研究对象,按随机数表法分为对照组(n=40)、实验组(n=40)。对照组患者用阿替普酶静脉溶栓治疗,实验组患者采用阿替普酶静脉溶栓联合阿托伐他汀治疗,比较两组治疗前后的临床疗效、血清白介素6(IL-6)、血清白介素8(IL-8)、超敏C-反应蛋白(hs-CRP)、NO合酶(NOS)、 一氧化氮(NO)、神经功能缺损量表(NIHSS)评分、Barthe指数评分及不良反应发生情况。结果:实验组患者治疗总有效率(92.50%)明显高于对照组(75.00%);治疗后,实验组患者 IL-6、IL-8和 hs-CRP 水平低于对照组,NOS和NO水平高于对照组,NIHSS评分低于对照组,Barthel指数评分高于对照组,实验组不良反应发生率(10.00%)明显低于对照组(27.50%)。结论:阿替普酶静脉溶栓联合阿托伐他汀治疗,能够明显抑制急性脑梗死患者炎症水平,改善患者神经功能,提高其生活质量,疗效好、安全性高,值得推广。

Objective To explore the effect of atteplase intravenous thrombolysis and atorvastatin on inflammatory factor levels in patients with acute cerebral infarction.Methods From January 2019 to June 2021,80 patients with acute cerebral infarction were divided into control and experimental groups,with 40 patients in each group.The control group was treated with atteplase intravenous thrombolysis,and the experimental group was treated with atteplase intravenous thrombolysis combined with atorvastatin to compare the clinical efficacy of the two groups before and after treatment,including serum interleukin 6(IL-6),serum interleukin 8(IL-8),and hypersensitive C-reactive protein (hs-CRP),NO synthase (NOS),NO (nitric oxide),neurological defects scale (NIHSS score,Barthe index) and the occurrence of adverse reactions.Results The total treatment rate in the experimental group (92.50%) was significantly higher than that in the control group (75.00%);After the treatment,The levels of IL-6,IL-8,and hs-CRP in the experimental group were lower than those in the control group;After the treatment,The eNOS and NO levels were higher in the experimental group than in the control group;After the treatment,The NIHSS score in the experimental group was lower than that in the control group,The Barthel index was higher than that in the control group;The incidence of adverse reactions in the experimental group (10.00%) was significantly lower than that in the control group (27.50%).Conclusion The treatment of atteplase intravenous thrombolysis and atorvastatin can significantly inhibit the inflammation level of patients with acute cerebral infarction,improve their neurological function,and thus improve the quality of life of patients.It has good efficacy and high safety,which is worth popularizing in clinical practice.